MSD In Q3 2012, MSD reported worldwide sales of $11.5 billion. What was the contribution that emerging markets had? From an MSD perspective, emerging markets refer to every market outside North America, Western Europe and Japan. Today, emerging markets contribute to around 18% of MSD’s total revenues. For the next 5…
MSD Belgium It truly seems that you have pharma in your genes, with a father who successfully developed a migraine drug in addition to your 4 years practicing medicine and now continuing an 18 year career with MSD. What distinguishes MSD as a pharmaceutical company in your opinion? At MSD, we are…
MSD Czech Republic Dr. Novotný, in 2008, you became Managing Director for MSD for the Czech and Slovak Republics. In the very next year after your appointment, you were tasked with managing the merger between MSD and Schering-Plough. How challenging was this undertaking, and what were the keys to its success? This was…
MSD South Africa If we take a look at MSD’s international presence, the group has grown into the third largest pharma company in the world. Here in South Africa, you are in the top ten. What are your aspirations? Our Aspiration is to consistently out grow the Market. With more than 10 brands…
Merck Sharp & Dohme (MSD) Romania You have only just arrived from Korea to head the Romanian operations at MSD. Just recently, you told in an interview with Medica Academica that MSD Romania enjoys a good reputation within MSD worldwide. Can you first elaborate to our readers what factors underlie this strong reputation? When I was…
Merck Sharp & Dohme (MSD) Malaysia Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in Malaysia? Since the merger last year with Schering-Plough, MSD has been #1 in the ethical category and we carry a heavy responsibility to remain…
MSD Mexico We read in an article by El Economista last year that you believe “there is no other company with such a diverse range of therapies as MSD and that makes you feel strong enough to continue growing in Mexico.” Can you please explain the thinking behind this statement, and what…
China MSD China’s Michel Vounastos gives his initial impressions of the opportunities and challenges inherent in the Chinese healthcare market, and highlights how MSD’s offerings are able to address specific gaps in the country. You just arrived in China in February. The country managers we’ve met have all been here for…
MSD Brasil When we were in Australia, we met with the “star scientist” Ian Frazier, who was Australian of the Year in 2009 for his co-discovery of Merck’s Gardasil. Or Singulair, which is the trade name of Montelukast, with the Mont signifying “Montreal” where the product was developed. What will it take…
MSD pharmaceuticals Pvt. Ltd. While your appointment as Managing Director was not a long time ago, you immediately faced the big task to oversee one of the most complicated corporate mergers the local Indian drug industry has seen in recent years. How challenging was the integration of Fulford and Organon for you? One of…
MSD Russia You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation prior to the interview, you mentioned that there has been a bit of a transition and adjustment period. How is…
Merck Sharp & Dohme Limited (MSD) You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the UK operations? As General Manager of the Merck/Schering-Plough Joint Venture in the US, I was responsible for the commercial operations…
See our Cookie Privacy Policy Here